Michelle Longmire, Medable CEO (Photo Credit: Jeff Rumans)

Med­able trots its way to uni­corn sta­tus amid vir­tu­al tri­al craze. Is a pub­lic de­but next?

As it be­comes ap­par­ent that de­cen­tral­ized clin­i­cal tri­als will like­ly be a part of drug­mak­ers’ strate­gies long af­ter the pan­dem­ic is over, a tech de­vel­op­er is gal­lop­ing its way to uni­corn sta­tus with a $304 mil­lion megaround.

Med­able un­veiled a hefty Se­ries D round on Tues­day — its fourth in the last year and a half — led by Black­stone Growth, Tiger Glob­al and GSR Ven­tures. The new cash brings the Pa­lo Al­to-based com­pa­ny’s to­tal raise to $521 mil­lion, with a whop­ping $2.1 bil­lion val­u­a­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA